483 related articles for article (PubMed ID: 29329590)
1. Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model.
Otsuka Y; Oikawa T; Yoshino H; Hashimoto S; Handa H; Yamamoto H; Hashimoto A; Sabe H
Cell Commun Signal; 2018 Jan; 16(1):1. PubMed ID: 29329590
[TBL] [Abstract][Full Text] [Related]
2. GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis.
Hashimoto A; Hashimoto S; Ando R; Noda K; Ogawa E; Kotani H; Hirose M; Menju T; Morishige M; Manabe T; Toda Y; Ishida S; Sabe H
PLoS One; 2011; 6(8):e23359. PubMed ID: 21858086
[TBL] [Abstract][Full Text] [Related]
3. The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis.
Sabe H; Hashimoto S; Morishige M; Ogawa E; Hashimoto A; Nam JM; Miura K; Yano H; Onodera Y
Traffic; 2009 Aug; 10(8):982-93. PubMed ID: 19416474
[TBL] [Abstract][Full Text] [Related]
4. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion.
Morishige M; Hashimoto S; Ogawa E; Toda Y; Kotani H; Hirose M; Wei S; Hashimoto A; Yamada A; Yano H; Mazaki Y; Kodama H; Nio Y; Manabe T; Wada H; Kobayashi H; Sabe H
Nat Cell Biol; 2008 Jan; 10(1):85-92. PubMed ID: 18084281
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer.
Matsumoto Y; Sakurai H; Kogashiwa Y; Kimura T; Matsumoto Y; Shionome T; Asano M; Saito K; Kohno N
Head Neck; 2017 Mar; 39(3):476-485. PubMed ID: 27880014
[TBL] [Abstract][Full Text] [Related]
6. High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
Tsutaho A; Hashimoto A; Hashimoto S; Hata S; Kachi S; Hirano S; Sabe H
Cell Commun Signal; 2020 Jun; 18(1):101. PubMed ID: 32580737
[TBL] [Abstract][Full Text] [Related]
7. Rab5c promotes AMAP1-PRKD2 complex formation to enhance β1 integrin recycling in EGF-induced cancer invasion.
Onodera Y; Nam JM; Hashimoto A; Norman JC; Shirato H; Hashimoto S; Sabe H
J Cell Biol; 2012 Jun; 197(7):983-96. PubMed ID: 22734003
[TBL] [Abstract][Full Text] [Related]
8. Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis.
Hashimoto S; Hirose M; Hashimoto A; Morishige M; Yamada A; Hosaka H; Akagi K; Ogawa E; Oneyama C; Agatsuma T; Okada M; Kobayashi H; Wada H; Nakano H; Ikegami T; Nakagawa A; Sabe H
Proc Natl Acad Sci U S A; 2006 May; 103(18):7036-41. PubMed ID: 16636290
[TBL] [Abstract][Full Text] [Related]
9. The EGFR-GEP100-Arf6 pathway in breast cancer: Full invasiveness is not from the inside.
Sabe H; Hashimoto S; Morishige M; Hashimoto A; Ogawa E
Cell Adh Migr; 2008; 2(2):71-3. PubMed ID: 19262097
[TBL] [Abstract][Full Text] [Related]
10. Loss of ASAP1 in the MMTV-PyMT model of luminal breast cancer activates AKT, accelerates tumorigenesis, and promotes metastasis.
Schreiber C; Gruber A; Roßwag S; Saraswati S; Harkins S; Thiele W; Foroushani ZH; Munding N; Schmaus A; Rothley M; Dimmler A; Tanaka M; Garvalov BK; Sleeman JP
Cancer Lett; 2022 May; 533():215600. PubMed ID: 35181478
[TBL] [Abstract][Full Text] [Related]
11. High expression of EPB41L5, an integral component of the Arf6-driven mesenchymal program, correlates with poor prognosis of squamous cell carcinoma of the tongue.
Otsuka Y; Sato H; Oikawa T; Onodera Y; Nam JM; Hashimoto A; Fukunaga K; Hatanaka KC; Hatanaka Y; Matsuno Y; Fukuda S; Sabe H
Cell Commun Signal; 2016 Nov; 14(1):28. PubMed ID: 27871329
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer.
Hashimoto A; Handa H; Hata S; Tsutaho A; Yoshida T; Hirano S; Hashimoto S; Sabe H
Cell Commun Signal; 2021 May; 19(1):54. PubMed ID: 34001163
[TBL] [Abstract][Full Text] [Related]
13. High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients.
Sato H; Hatanaka KC; Hatanaka Y; Hatakeyama H; Hashimoto A; Matsuno Y; Fukuda S; Sabe H
Cell Commun Signal; 2014 Mar; 12():17. PubMed ID: 24621372
[TBL] [Abstract][Full Text] [Related]
14. Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities.
Onodera Y; Hashimoto S; Hashimoto A; Morishige M; Mazaki Y; Yamada A; Ogawa E; Adachi M; Sakurai T; Manabe T; Wada H; Matsuura N; Sabe H
EMBO J; 2005 Mar; 24(5):963-73. PubMed ID: 15719014
[TBL] [Abstract][Full Text] [Related]
15. Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth.
Mao SPH; Park M; Cabrera RM; Christin JR; Karagiannis GS; Oktay MH; Zaiss DMW; Abrams SI; Guo W; Condeelis JS; Kenny PA; Segall JE
Breast Cancer Res; 2018 Oct; 20(1):131. PubMed ID: 30367629
[TBL] [Abstract][Full Text] [Related]
16. GEP100 regulates epidermal growth factor-induced MDA-MB-231 breast cancer cell invasion through the activation of Arf6/ERK/uPAR signaling pathway.
Hu Z; Xu R; Liu J; Zhang Y; Du J; Li W; Zhang W; Li Y; Zhu Y; Gu L
Exp Cell Res; 2013 Aug; 319(13):1932-1941. PubMed ID: 23747719
[TBL] [Abstract][Full Text] [Related]
17. Arf6 and its ZEB1-EPB41L5 mesenchymal axis are required for both mesenchymal- and amoeboid-type invasion of cancer cells.
Handa H; Hashimoto A; Hashimoto S; Sabe H
Small GTPases; 2018 Sep; 9(5):420-426. PubMed ID: 27754741
[TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer.
Hashimoto S; Mikami S; Sugino H; Yoshikawa A; Hashimoto A; Onodera Y; Furukawa S; Handa H; Oikawa T; Okada Y; Oya M; Sabe H
Nat Commun; 2016 Feb; 7():10656. PubMed ID: 26854204
[TBL] [Abstract][Full Text] [Related]
19. Contributions of the RhoA guanine nucleotide exchange factor Net1 to polyoma middle T antigen-mediated mammary gland tumorigenesis and metastasis.
Zuo Y; Ulu A; Chang JT; Frost JA
Breast Cancer Res; 2018 May; 20(1):41. PubMed ID: 29769144
[TBL] [Abstract][Full Text] [Related]
20. CIN85, a Cbl-interacting protein, is a component of AMAP1-mediated breast cancer invasion machinery.
Nam JM; Onodera Y; Mazaki Y; Miyoshi H; Hashimoto S; Sabe H
EMBO J; 2007 Feb; 26(3):647-56. PubMed ID: 17255943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
